Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells. Gardiquimod is an imidazoquinoline analog and is a TLR7/8 agonist. When used at concentrations below 10 μM, Gardiquimod specifically activates TLR7.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 7,000 | |||
2 mg | 在庫あり | ¥ 10,000 | |||
5 mg | 在庫あり | ¥ 16,000 | |||
10 mg | 在庫あり | ¥ 26,000 | |||
25 mg | 在庫あり | ¥ 43,500 | |||
50 mg | 在庫あり | お問い合わせ | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 18,500 |
説明 | Gardiquimod could inhibit HIV-1 infection of macrophages and activated peripheral blood mononuclear cells. Gardiquimod is an imidazoquinoline analog and is a TLR7/8 agonist. When used at concentrations below 10 μM, Gardiquimod specifically activates TLR7. |
In vitro | Administration of 6-60?μM Gardiquimod obviously inhibits HIV-1 reverse transcriptase cDNA synthesis[1]. |
In vivo | Gardiquimod (1 mg/kg per mouse; i.p.; daily for 7 days) in combination with Dendritic cells (DCs) enhance the anti-tumor effects of NK cells[2]. |
分子量 | 313.4 |
分子式 | C17H23N5O |
CAS No. | 1020412-43-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 18 mg/mL (57.43 mM)
DMF: 18 mg/mL (57.43 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Gardiquimod 1020412-43-4 Immunology/Inflammation Microbiology/Virology Proteases/Proteasome HIV Protease TLR HIV-1 HepG2 Toll-like Receptor (TLR) Inhibitor PBMCs inhibit HIV cells peripheral macrophages blood liver carcinoma Human immunodeficiency virus mononuclear inhibitor